Tuesday, August 16, 2022
SCIENMAG: Latest Science and Health News
No Result
View All Result
  • Login
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
No Result
View All Result
Scienmag - Latest science news from science magazine
No Result
View All Result
Home SCIENCE NEWS Medicine & Health

Overcoming resistance

August 31, 2018
in Medicine & Health
0
Share on FacebookShare on Twitter
IMAGE

Credit: Beth Israel Deaconess Medical Center

The maintenance workers of the vascular system, pericyte cells envelop the surface of blood vessels, supporting their stability, growth and survival. Given that blood vessel growth is one necessary component in tumor development and progression, researchers have lately been investigating the stem cell-like pericytes' role in cancer.

In a recent paper published in the journal Clinical Cancer Research (CCR), Carmelo Nucera, MD, PhD, primary investigator in the thyroid cancer research program in the Division of Experimental Pathology in BIDMC's Department of Pathology, and colleagues investigated the role of pericytes as part of the tumor microenvironment in the subset of papillary thyroid cancers modulated by a mutation of the BRAF cancer-promoting gene.

Nucera and colleagues evaluated the efficacy of BRAFV600E inhibitors, which are used to target the tumor's mutation and act as therapeutic agents, both alone and in combination with another agent targeting the tyrosine kinase (TK) receptor-pathway mediated by pericytes. The scientists demonstrated that the combination therapy blocked tumor cell proliferation, increased cell death and otherwise damaged tumor cells in vitro. However, the team also showed that pericyte cells, in response to the therapy, released molecules to overcome the lethal effects of the drugs on the tumor cells.

"Our findings suggest that pericytes may be a double-edged sword in BRAFV600E therapy for metastatic and resistant papillary thyroid cancer, as they secrete factors that trigger resistance to BRAFV600E and TK inhibitors," said Nucera, who is also an Assistant Professor at Harvard Medical School. "However, targeting these factors in turn might represent a novel therapeutic strategy with translational applications in clinical trials for patients with this type of aggressive tumors that have become resistant to conventional treatments including radioactive iodine."

###

Nucera's co-authors include co-lead authors Alessandro Prete and Agnes S. Lo, Swati S. Bhasin, Zeus A. Antonello, Danica M. Vodopivec, Soumya Ullas, Jennifer N. Sims, John Clohessy, Ann M. Dvorak, Tracey Sciuto, Manoj Bhasin, Jack Lawler, and S. Ananth Karumanchi of BIDMC; Peter M. Sadow of Massachusetts General Hospital; and Joanne E. Murphy-Ullrich of University of Alabama at Birmingham.

This work was supported by grants from the National Cancer Institute/National Institutes of Health (1R21CA165039-01A1 and 1R01CA18118301A1); the American Thyroid Association (ATA); ThyCa:Thyroid Cancer Survivors Association Inc. for Thyroid Cancer Research; the Guido Berlucchi Young Investigator research award 2013; and BIDMC/CAO Grants; and NIH grant 1R01CA175012.

Media Contact

Jacqueline Mitchell
[email protected]
617-667-7306
@BIDMCNews

http://www.bidmc.harvard.edu

http://dx.doi.org/10.1158/1078-0432.CCR-18-0693

Share25Tweet16Share4ShareSendShare
  • Amanda Poholek, Ph.D.

    Reinvigorating ‘lost cause’ exhausted T cells could improve cancer immunotherapy

    138 shares
    Share 55 Tweet 35
  • The best way to take pills according to science

    66 shares
    Share 26 Tweet 17
  • Nuclear war would cause a global famine and kill billions, Rutgers-led study finds

    65 shares
    Share 26 Tweet 16
  • 1 in 3 parents worry that school traffic is a danger for kids

    65 shares
    Share 26 Tweet 16
  • Exercise answer: Research shows it’s how often you do it, not how much

    64 shares
    Share 26 Tweet 16
  • The North American Menopause Society releases its 2022 Hormone Therapy Position Statement

    149 shares
    Share 60 Tweet 37
ADVERTISEMENT

About us

We bring you the latest science news from best research centers and universities around the world. Check our website.

Latest NEWS

Reinvigorating ‘lost cause’ exhausted T cells could improve cancer immunotherapy

Experts optimistic about converting coal plants to production of clean geothermal energy

A role for cell ‘antennae’ in managing dopamine signals in the brain

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 193 other subscribers

© 2022 Scienmag- Science Magazine: Latest Science News.

No Result
View All Result
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US

© 2022 Scienmag- Science Magazine: Latest Science News.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In